Vectus Biosystems Limited Overview
Vectus Biosystems is a Sydney-based, clinical-stage micro-cap drug developer built on a library of more than 1,000 orally available small-molecule mimetics derived from vasoactive-peptide biology discovered by co-founder Dr Karen Duggan. Its lead asset, VB0004, has completed Phase Ia and Phase Ib human safety studies in Australia and is now being repositioned, under CEO/CTO Dr Tara Speranza (appointed May 2026), toward idiopathic pulmonary fibrosis (IPF), an orphan indication with roughly 95,000–100,000 US patients and only three approved drugs, none of which reverse fibrosis. The company operates a capital-light "develop, validate, partner" model, having monetised its renal compound VB4-P5 through an equity-for-IP sale to Nasdaq-listed XORTX Therapeutics in April 2026. With c.A$0.72m cash at 30 June 2026, A$2.8m of XORTX securities (at 30 June 2026 fair value), a director loan and a going-concern material uncertainty, Vectus is a binary, financing-dependent option on VB0004's regulatory and partnering path.
What the company does. Vectus discovers and develops small-molecule therapeutics intended not only to slow but to reverse pathological fibrosis (tissue scarring) in major organs. Its stated franchise targets are cardiac, renal (kidney), hepatic (liver) and pulmonary (lung) fibrosis. The scientific origin is Dr Duggan's clinical observation that patients with hypertensive renal fibrosis and cardiac fibrosis had very low levels of vasoactive intestinal peptide (VIP) in affected tissue; rather than develop injectable peptides for older, sick patients, she worked with chemists to design orally dosed small-molecule mimetics of the receptor-binding regions of the peptide (Biotech Daily, 31 July 2026). The company describes VB0004 as a first-in-class oral Natriuretic Peptide Receptor C (NPR-C) agonist (CHRS engagement announcement, 13 July 2026).
Company's own description (FY2026 Annual Report, paraphrased). The principal activity is medical research and development. The company describes FY2026 as the start of a "new era": new leadership, completion of the XORTX transaction for VB4-P5, a A$791,000 placement, and the establishment of a US regulatory pathway for VB0004 in IPF. The Review of Operations states the company is now focused on taking VB0004 into a further Phase Ib study targeting IPF, an indication eligible for Orphan Drug Designation (ODD), while maintaining its broad IP and drug library of more than 1,000 compounds as a source of partnering and licensing opportunities under a capital-efficient model.
Business model. Vectus does not manufacture or sell product. Its model is to (i) generate preclinical and early clinical validation data in-house or via CROs, (ii) protect compounds with patents, (iii) package assets in a data room, and (iv) transact with pharmaceutical/biotech partners via licences, co-development, or asset sales. Its FY2026 Chairman's Report frames the XORTX deal as proof that this model can produce transactions.
Revenue model mix (FY2026, A$, FY2026 AR Note 3).
Product, service and subscription revenue: nil. Licensing royalties/milestones: nil (the XORTX deal was structured as an outright sale for equity; the CEO told Biotech Daily the company would normally prefer milestones and royalties but the asset was very early-stage). A separate A$204,077 fair-value gain on revaluation of XORTX securities was recognised below the revenue line.
Value chain position. Upstream discovery and early clinical development (Phase I). Vectus outsources clinical execution (Nucleus Network for Phase Ia/Ib; Syneos Health work order 2021), GMP manufacture/stability (Asymchem Laboratories stability studies, 2024), regulatory agency (Cardinal Health Regulatory Services, 2026) and business development (C14 Consulting Group, LLC).
Customer types. The company's "customers" are prospective licensees and acquirers: global and mid-cap pharmaceutical companies and biotechs with antifibrotic, nephrology, hepatology or respiratory franchises. XORTX Therapeutics (Canada/Nasdaq, kidney disease and gout focus) is the only counterparty to date.
End-markets served (prospective). IPF (lead indication from 2026); progressive pulmonary fibrosis (VB4-A79); liver fibrosis/MASH (VB4-A32); cardiac fibrosis and hypertension (VB0004 historical focus); renal fibrosis (VB4-P5, now owned by XORTX for renal/kidney uses; Vectus retains a licence for other fields). Accugen addresses molecular diagnostics/laboratory PCR quantitation but has generated no disclosed revenue.
Independent characterisation. Vectus is a single-asset, sub-A$10m clinical-stage biotech with a long history (listed 2016) of slow progress, very limited cash, and dependence on the R&D Tax Incentive, director funding and small placements. FY2026's headline profit (A$1.56m) is an accounting artefact of a non-cash asset sale and should not be read as operating viability: underlying cash operating outflow was A$573,395. The genuine strategic change in 2026 is the pivot from broad cardiovascular/renal ambitions to a focused orphan-indication regulatory pathway in IPF, led by a CEO with transaction experience.
Strategy
Stated strategy themes (FY2026 Annual Report, paraphrased).
-
A new era under new leadership: the CEO is articulating a clearer, more disciplined development strategy, directing resources to the opportunities most capable of generating clinical and commercial value, with initial emphasis on VB0004.
-
Commercialise IP through partnerships: engagement with potential pharmaceutical partners directly and via C14; data room access for selected parties; licensing, collaborative development and other strategic transactions on an asset-by-asset basis.
-
Validate then partner: develop and carry out early validation of candidates until they are commercially attractive to partners — exemplified by the XORTX transaction.
-
Orphan regulatory pathway for VB0004 in IPF: ODD request, pre-IND interactions and an IND via CHRS; further Phase Ib in IPF context; global Phase IIb thereafter.
-
Capital efficiency: focus on high-value opportunities; continued cost discipline.
Strategic initiatives in the last 24 months.
Sustainability/ESG commitments: None published.
Medium-term financial targets/guidance: None. The Directors' Report states that likely developments and expected results have been omitted because disclosure would likely result in unreasonable prejudice to the Group. Operational intentions communicated by the CEO (Biotech Daily, July 2026): appoint a CRO for a randomised Phase Ib MAD study of up to 50 volunteers; a "best guess" of recruitment completion by end-2026, with the study not expected to exceed six months once started; global Phase IIb under IND thereafter. The CEO acknowledged further capital raising will be required.
Products & Services
All assets fall within the single pharmaceutical R&D segment. No product is approved or marketed; pricing models are not publicly disclosed for any asset.
VB0004 — lead clinical asset
Description: Orally administered small-molecule mimetic designed from vasoactive peptide receptor-binding regions; described by the company as a first-in-class oral NPR-C agonist. The CEO describes a dual mechanism: activating calcium entry and other pathways that down-regulate pro-fibrotic factors, plus activating macrophage precursors that clear fibrotic debris (Biotech Daily, Jul 2026). Note: Biotech Daily's description of the receptor differs in wording from the company's NPR-C characterisation; the company's announcement is treated as authoritative.
Target indications: Idiopathic pulmonary fibrosis (lead from 2026); historically hypertension-associated cardiac and renal fibrosis; company positions VB0004 for prevention and reversal of fibrosis in lungs, heart and kidneys (placement announcement, May 2026).
Key data: - Preclinical: bleomycin rat lung-fibrosis model — fibrotic area c.20% at 2 weeks, 23% at 4 weeks; VB0004-treated animals at 16 weeks reduced to 14% (CEO interview, Biotech Daily, Jul 2026). Peer-reviewed publication of this study is not publicly disclosed.
-
Phase Ia (Australia, Nucleus Network, commenced Aug 2021): single and multiple ascending dose cohorts in healthy volunteers; Trial Safety Committee reviewed all five cohorts; favourable safety (FY2022 AR).
-
Phase Ib (finalised April 2024): healthy volunteers and patients with mild–moderate hypertension; no adverse events attributed to VB0004 (FY2025 AR). Pharmacokinetics: Tmax 6–8 hours; plasma half-life 10–15 hours on Days 1 and 14, supporting once-daily dosing (company data as reported by Simply Wall St and Biotech Daily). CEO reports blood-pressure lowering in mildly hypertensive participants as a sign of pharmacological activity.
-
CMC: validated GMP manufacture at what the company calls an attractive cost per dose; long shelf life; amenable to scale-up (FY2025 AR).
Development status / next steps: FDA pre-IND Type B meeting granted (30 Sep 2026; written responses expected by mid-November 2026); Orphan Drug Designation request in preparation via CHRS; planned randomised Phase Ib MAD study enrolling up to 50 healthy volunteers, 21 days of dosing plus 7-day follow-up, with a CRO to be appointed; subsequently a global Phase IIb under a US IND (CEO, Biotech Daily, Jul 2026).
Target customer: Licensing partner with respiratory/antifibrotic franchise.
Launch year: Not applicable (pre-commercial).
Pricing: Not publicly disclosed.
VB4-A79 — pulmonary fibrosis preclinical lead
Description: Library-derived compound reported to reverse fibrosis in the lung in preclinical work (FY2022 Appendix 4E). Selected as an emerging lead for lung fibrosis (FY2025 AR). Included in C14's partnering outreach (FY2026 AR).
Status: Preclinical; no clinical timetable disclosed.
VB4-A32 — liver fibrosis preclinical lead
Description: Emerging lead targeting liver fibrosis, including non-alcoholic steatohepatitis (now termed MASH) per company/aggregator descriptions (FY2025 AR; Pearler profile).
Status: Preclinical; included in partnering outreach.
VB4-P5 — renal fibrosis compound (divested for renal/kidney uses)
Description: Small molecule targeting renal fibrosis. Sold to XORTX Therapeutics Inc. (term sheet 17 Oct 2025; closed 14 Apr 2026). XORTX acquired the patents, IP and data relating to VB4-P5 for renal fibrosis and kidney disease; Vectus retained a licence for applications outside those fields (FY2026 AR).
Consideration: 154,544 XORTX common shares (c.9.9% at completion) and 692,150 pre-funded warrants (nil-cost exercise), valued at A$2,593,994 at closing; carried at A$2,798,071 at 30 June 2026 (shares A$510,722; warrants A$2,287,349).
Drug library (>1,000 compounds)
Description: Patented library of small-molecule mimetics derived from the platform underpinning VB0004; offered to partners for licensing (FY2025/FY2026 AR). Granted patents cover both the molecules and a proprietary method of manufacture (FY2025 AR).
Accugen platform (subsidiary Accugen Pty Limited)
Description: Reagents (AccuCal, AccuCal-D) and RealCount software for improving the speed and accuracy of DNA/RNA quantitation in laboratory PCR. Patents granted in Thailand and South Korea (FY2022). Evaluation kits were distributed to key opinion leaders (FY2022 half-year report).
Status: No revenue or commercialisation activity disclosed in FY2025 or FY2026 annual reports; treated as dormant/non-core.
Financial Narrative
Income statement
Sources and notes: FY2024–FY2026 from FY2025 and FY2026 audited Annual Reports (FY2025 restated). FY2022–FY2023 revenue, R&D, opex, EBIT, EBITDA and finance costs are aggregator-derived (StockAnalysis) and flagged as such; FY2022–FY2023 net loss and EPS from the FY2026/FY2025 Remuneration Report five-year table. FY2022 Appendix 4E reported a loss of A$3,993,775 versus A$3,969,886 in the five-year table (minor discrepancy). FY2025 as originally reported: loss A$1,777,259, EPS -3.34c, R&D A$667,811; restated: loss A$1,862,377, EPS -3.50c, R&D A$752,929. EBITDA computed as pre-tax income + finance costs + depreciation (FY2024: D&A A$58,835; FY2025: A$13,690; FY2026: A$4,597). Gross margin is not meaningful (no cost of sales; all income is other income). Operating margin equals EBIT/revenue and tracks the EBITDA margin.
Revenue CAGR FY2022–FY2026: c.20.8% p.a. — not meaningful; FY2026 is inflated by a one-off, non-cash asset sale. Excluding the XORTX gain, FY2026 revenue and other income was A$216k, implying a CAGR of roughly -36% p.a. over four years, reflecting declining R&D tax offsets as research activity was wound down.
Commentary. The five-year P&L shows a company in managed contraction. Operating expenses fell from c.A$4.6m (FY2022–FY2023, Phase Ia/Ib execution) to A$1.41m in FY2026 (–69%). R&D expense collapsed from A$2.54m to A$0.17m, of which A$172,020 was patent costs and only A$978 was research (FY2026 AR Note 4) — i.e., Vectus spent essentially nothing on new science in FY2026. Because the R&D Tax Incentive refunds a percentage of eligible spend, declining R&D mechanically reduced refundable offset income (A$1.06m FY2024 → A$0.21m FY2026). The inflection to profit in FY2026 is entirely attributable to the XORTX consideration (A$2.55m net) and subsequent fair-value gain (A$0.20m); excluding these, FY2026 would have been a loss of approximately A$1.20m. Finance costs rose to A$44k in FY2026 from interest on the Stang loan (A$42,607, capitalised). FY2022's elevated finance costs (c.A$0.69m) reflected convertible notes that were converted to equity in FY2022–FY2023.
Balance sheet
Sources and notes: FY2024–FY2026 from FY2026 AR (restated FY2024 and FY2025). FY2024 as originally reported: total assets A$2,025,627, equity A$1,486,365; FY2025 as originally reported: total assets A$782,656, equity deficit A$256,622. FY2022 equity deficit A$3,533,995 and cash A$1,281,341 from FY2022 Appendix 4E; other FY2022–FY2023 balances from StockAnalysis (agg.); FY2022 current liabilities included c.A$5.45m convertible notes and c.A$0.44m short-term debt. FY2023 equity: FY2025 AR statement of changes in equity shows A$3,767,334 at 1 July 2023, while the FY2024 Appendix 4E stated A$3,523,504 — a A$244k discrepancy (both noted; the audited figure is used). FY2026 debt comprises Stang loan A$487,001 (incl. A$37,001 capitalised interest), insurance premium funding A$43,498 and lease liabilities A$16,166. Unrecognised deferred tax assets on revenue losses: A$6,022,666 at 30% (implying c.A$20m of carried-forward tax losses).
Commentary. The balance sheet has swung between distress and modest solvency. FY2022 ended with an equity deficit because of convertible notes, cured in FY2023 through conversions and a c.A$4.6m raise. Steady cash burn then eroded equity to a deficit again at 30 June 2025 (restated -A$81k). In FY2026 the XORTX securities (A$2.80m, 73% of total assets) restored positive equity of A$2.32m. Critically, the dominant asset is a minority stake in a sub-US$5m Nasdaq micro-cap, so balance-sheet strength is highly sensitive to XORTX's share price. Liabilities include A$278,885 of accrued but unpaid directors' fees and A$373,229 payable to Stang-related Regional Corporate Services — i.e., insiders are effectively financing operations through deferral.
Cash flow
Sources and notes: FY2024–FY2026 audited cash flow statements. FY2022 operating cash burn A$4,462,232 per FY2022 Appendix 4E; FY2023 operating cash burn A$2,352,742 per FY2024 Appendix 4E; FY2023 equity raise c.A$4.6m per FY2025 AR going-concern note. FY2022 net change in cash derived from cash of A$5.78m (FY2021, agg.) to A$1.28m. FY2025 investing inflow of A$101,033 from disposal of laboratory equipment.
Commentary. Gross operating payments fell 72% in two years (A$3.62m FY2024 → A$1.00m FY2025... → A$1.00m FY2026 after a further cut to A$1.0m), reflecting laboratory closure, staff reduction and the move to Rosebery. Quarterly disclosure shows the trough: cash of A$569k (Sep 2025 qtr), A$330k (Dec 2025), A$94k (Mar 2026; quarterly operating outflow A$236k), recovering to A$718k (Jun 2026) after the placement, with June-quarter outflows of c.A$167k. The June 2026 Appendix 4C implied c.4.3 quarters of funding (Biotech Daily). No free cash flow has ever been generated; the company has relied on equity, convertible notes, director loans and R&D refunds.
Ratios
Notes: Analyst calculations on average balances. ROE "NA" where average equity is negative or spans a sign change (not meaningful). Net debt/EBITDA not meaningful in any year (net cash in FY2023–FY2026; negative EBITDA FY2022–FY2025; FY2026 EBITDA non-cash). ROIC not meaningful (no invested operating capital; equity-funded R&D). Cash conversion cycle not applicable (no inventory, receivables or trade cycle). FY2026 ROE/ROA/interest-cover figures are inflated by the non-cash XORTX gain and carry no signal about operating performance.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Entities
| Entity | Ownership | Jurisdiction | Function |
|---|---|---|---|
Vectus Biosystems Limited | Parent (ASX-listed) | Australia | Drug discovery and development; holds drug IP; head of tax-consolidated group |
Accugen Pty Limited | 100% | Australia | Owns Accugen PCR quantitation platform (AccuCal reagents and RealCount software); no disclosed revenue |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue and other income (AUD K) | 1,139 | 478 | 2,767 |
Segment pre-tax profit/loss (AUD K) | -2,338 | -1,862 | 1,559 |
Segment pre-tax margin (%) | -205.3 | -389.5 | 56.3 |
YoY revenue growth (%) | -15.6 | -58.0 | 478.7 |
Contribution to group revenue (%) | 100 | 100 | 100 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue and other income (AUD K) | 1,300 | 1,350 | 1,139 | 478 | 2,767 |
R&D tax offset income (AUD K) | — | — | 1,061 | 461 | 210 |
Interest income (AUD K) | — | — | 77 | 19 | 7 |
Net gain on VB4-P5 sale to XORTX (AUD K) | 0 | 0 | 0 | 0 | 2,551 |
Fair value gain on XORTX securities (AUD K) | 0 | 0 | 0 | 0 | 204 |
Gross profit (AUD K, no cost of sales) | 1,300 | 1,350 | 1,139 | 478 | 2,767 |
Research and development expense (AUD K) | 2,540 | 1,960 | 1,151 | 753 | 173 |
Employee benefits and directors remuneration (AUD K) | — | — | 1,303 | 519 | 406 |
Administration and corporate expense (AUD K) | — | — | 777 | 949 | 771 |
Total operating expenses, company definition (AUD K) | 4,600 | 4,590 | 3,477 | 2,341 | 1,412 |
Operating income EBIT (AUD K) | -3,300 | -3,240 | -2,329 | -1,858 | 1,603 |
EBITDA (AUD K) | -3,280 | -3,180 | -2,271 | -1,845 | 1,607 |
Finance costs (AUD K) | 690 | 200 | 9 | 4 | 44 |
Pre-tax income (AUD K) | -3,970 | -3,442 | -2,338 | -1,862 | 1,559 |
Net income (AUD K) | -3,970 | -3,442 | -2,338 | -1,862 | 1,559 |
EPS basic (A$ cents) | -11.89 | -7.18 | -4.39 | -3.50 | 2.87 |
EPS diluted (A$ cents) | -11.89 | -7.18 | -4.39 | -3.50 | 2.81 |
Dividends per share (A$ cents) | 0 | 0 | 0 | 0 | 0 |
Net margin (%) | -307.2 | -254.1 | -205.3 | -389.5 | 56.3 |
EBITDA margin (%) | -252.3 | -235.4 | -199.4 | -385.8 | 58.1 |
Balance Sheet and Share Count (millions)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash and cash equivalents (AUD K) | 1,281 | 2,951 | 809 | 251 | 719 |
Investments in XORTX securities (AUD K) | 0 | 0 | 0 | 0 | 2,798 |
Total current assets (AUD K) | 3,730 | 4,460 | 1,877 | 850 | 3,801 |
Total assets (AUD K) | 3,940 | 4,630 | 2,286 | 854 | 3,818 |
Total current liabilities (AUD K) | 7,400 | 830 | 535 | 732 | 1,004 |
Total liabilities (AUD K) | 7,474 | 863 | 539 | 935 | 1,499 |
Short-term debt incl. leases and premium funding (AUD K) | 5,950 | 40 | 29 | 0 | 52 |
Long-term debt incl. director loan and leases (AUD K) | 0 | 0 | 0 | 200 | 495 |
Total debt (AUD K) | 5,950 | 40 | 29 | 200 | 547 |
Net debt, negative equals net cash (AUD K) | 4,669 | -2,911 | -780 | -51 | -172 |
Total equity (AUD K) | -3,534 | 3,767 | 1,747 | -81 | 2,319 |
Goodwill and intangibles (AUD K) | 0 | 0 | 0 | 0 | 0 |
Working capital (AUD K) | -3,670 | 3,630 | 1,343 | 118 | 2,797 |
Accumulated losses (AUD K) | — | -35,388 | -37,466 | -39,328 | -37,769 |
Ordinary shares on issue (millions) | — | 53.19 | 53.21 | 53.28 | 61.69 |
Cash Flow
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow (AUD K) | -4,462 | -2,353 | -2,033 | -830 | -573 |
R&D tax refund received within OCF (AUD K) | — | — | 1,516 | 977 | 422 |
Payments to suppliers and employees (AUD K) | — | — | -3,617 | -1,822 | -1,002 |
Capital expenditure (AUD K) | — | — | 68 | 0 | 0 |
Free cash flow (AUD K) | — | — | -2,101 | -830 | -573 |
Proceeds from share issues (AUD K) | — | 4,600 | 0 | 0 | 791 |
Director loan drawdowns (AUD K) | — | — | 0 | 200 | 250 |
Dividends paid (AUD K) | 0 | 0 | 0 | 0 | 0 |
Share buybacks (AUD K) | 0 | 0 | 0 | 0 | 0 |
Net change in cash (AUD K) | -4,500 | 1,670 | -2,142 | -558 | 468 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on equity (%) | — | — | -84.8 | — | 139.3 |
Return on assets (%) | -72.7 | -80.3 | -67.6 | -118.6 | 66.7 |
Current ratio (x) | 0.50 | 5.37 | 3.51 | 1.16 | 3.78 |
Debt to equity (x) | — | 0.01 | 0.02 | — | 0.24 |
Asset turnover (x) | 0.24 | 0.32 | 0.33 | 0.30 | 1.18 |
Interest coverage EBIT to finance costs (x) | -4.8 | -16.2 | -258.8 | -464.5 | 36.4 |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia: R&D tax offset and interest income (AUD K) | 1,138 | 480 | 217 |
North America: VB4-P5 sale consideration from XORTX, Canada/Nasdaq (AUD K) | 0 | 0 | 2,551 |
Other regions (AUD K) | 0 | 0 | 0 |
Total revenue and other income (AUD K) | 1,139 | 478 | 2,767 |
Share Price and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.985 | 0.44 | 0.077 | 0.04 | 0.125 |
Annual share price change (%) | -27.0 | -55.3 | -82.5 | -48.1 | 212.5 |
Market capitalisation at 30 June (AUD Mn) | — | 23.4 | 4.1 | 2.1 | 7.7 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Valuation Snapshot
| Multiple | Value | Comment |
|---|---|---|
Market capitalisation | c.A$6.8m | 62.0–62.2m shares |
Enterprise value (market cap – cash A$0.72m + debt A$0.55m) | c.A$6.7m | 30 June 2026 balance sheet |
EV adjusted for XORTX securities (A$2.80m at 30 June 2026) | c.A$3.9m | Lower if XORTX mark-to-market decline applied |
P/E (trailing) | c.3.9x | Not meaningful (non-cash, non-recurring gain) |
EV/EBITDA | c.4.2x | Not meaningful (same reason) |
EV/Sales | c.2.4x | Not meaningful |
P/B | c.2.9x (book A$2.32m; book value per share A$0.037 per Market Index) | Book dominated by XORTX stake |
Capital Instruments
| Instrument | Amount (AUD) | Rate | Maturity / terms |
|---|---|---|---|
Unsecured loan from Maurie Stang (incl. A$37,001 capitalised interest) | 487,001 | ATO benchmark rate (8.6% weighted rate disclosed) | Classified non-current; repayable from future R&D refunds or other funds; may be repaid early without penalty subject to Board approval if alternative funding secured. Facility up to A$550k (A$450k principal drawn) |
Insurance premium funding | 43,498 | — | Current (<1 year) |
Lease liabilities | 16,166 | — | A$8,383 current; A$7,783 non-current |
“—” = not publicly disclosed.
Analyst Conclusions
Management guidance. No financial guidance is provided (omitted on grounds of unreasonable prejudice). Operational intentions: FDA pre-IND written responses by mid-November 2026; ODD request for VB0004 in IPF; appointment of a CRO for a randomised Phase Ib MAD study (up to 50 healthy volunteers, 21-day dosing, 7-day follow-up); global Phase IIb under IND thereafter; continued partnering of VB0004, VB4-A32, VB4-A79 and the library; potential gradual sale of XORTX securities. Further capital raising is expected.
Consensus growth expectations. None (no broker coverage).
Bull case
-
Regulatory de-risking creates a partnering inflection. A constructive FDA pre-IND response and ODD grant would convert VB0004 from a stalled cardiovascular asset into an orphan IPF programme with a clear IND pathway. Given Lilly's US$99m upfront for Mediar's early IPF asset, even a modest licence for VB0004 could exceed Vectus' entire c.A$6.8m market capitalisation.
-
Hidden asset value and capital efficiency. At 30 June 2026 Vectus held A$3.52m of cash plus XORTX securities against a market capitalisation of c.A$6.8m, implying the market ascribes only c.A$3–4m to VB0004, two preclinical leads and a >1,000-compound library. Quarterly cash burn of c.A$170k gives the company unusually long runway per dollar raised.
-
Execution-capable leadership. The XORTX deal closed within seven months of Dr Speranza's consultancy start and the regulatory programme was established within five months of her CEO appointment; her Protelos/Servier history and milestone-linked ZEPOs (hurdles at A$0.20–0.30) align her with shareholders.
Bear case
-
Funding gap is existential. Cash of A$0.72m cannot fund a Phase Ib study and IND-enabling work, let alone Phase IIb. The auditor's material uncertainty persists; the company depends on director loans, fee deferrals and family-office placements, and further dilution at depressed prices is likely.
-
The XORTX stake may be worth far less than its carrying value. XORTX's market capitalisation is c.US$3.1m and its share price fell c.21% after 30 June 2026; Vectus' 846,694 securities are large relative to XORTX's float and illiquid. Realisable value could be well below A$2.8m.
-
Unproven efficacy in a crowded field. VB0004 has no patient efficacy data in IPF; key preclinical lung data have been described in media interviews rather than peer-reviewed disclosure; nerandomilast's 2025 approval and late-stage competitors raise the bar; and two years of C14 outreach have not yet produced a VB0004 licence.
Key catalysts and monitorables (next 12 months).
Analyst verdict.
Vectus Biosystems enters late 2026 materially better positioned than a year earlier, but it remains a deeply speculative, financing-constrained micro-cap whose value rests almost entirely on the regulatory and partnering trajectory of a single asset. The FY2026 "profit" of A$1.56m is an accounting by-product of exchanging the VB4-P5 renal compound for XORTX equity; underlying operations consumed A$573k of cash, research spending was essentially zero, and the auditor again flagged a material uncertainty over going concern. Strip out the XORTX stake and the company held A$0.72m of cash against A$1.50m of liabilities, much of it owed to insiders.
What has genuinely changed is direction and execution. Under Dr Tara Speranza, Vectus has abandoned the diffuse cardiovascular-renal narrative that defined its first decade in favour of an orphan IPF strategy with tangible near-term milestones: CHRS appointed in July, a pre-IND Type B meeting granted in September, and an ODD package in preparation. VB0004's clean Phase Ia/Ib safety record and once-daily oral profile are real assets; its claimed fibrosis-reversal mechanism, if replicated in patients, would be differentiated even after nerandomilast's approval.
The investment case therefore reduces to a sequence of binary events — FDA feedback in November 2026, ODD, the ability to raise enough capital to complete a Phase Ib without crippling dilution, and a partner willing to fund Phase II. The market capitalisation of roughly A$6.8m, of which perhaps half is notionally backed by cash and XORTX securities, prices in a high probability of failure; the option value is consequently significant if milestones land. Governance (related-party funding, limited independence, a recent restatement) and the illiquid XORTX holding are meaningful offsets.
Verdict: a high-risk, event-driven special situation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education |
|---|---|---|---|---|
Dr Tara Speranza | Chief Executive Officer and Chief Technology Officer | CEO/CTO since 7 May 2026; consultant since August 2025 | Senior research positions at the University of Sydney and University of Geneva (novel molecular targets, translational drug development); led a commercial partnership with Servier that resulted in development and commercialisation of the osteoporosis drug Protelos (strontium ranelate); analyst at Bell Potter; role at Tenmile (Andrew Forrest-associated investment group); investment, advisory and capital-markets roles in healthcare/biotech | PhD, University of Sydney (molecular biology; Protelos work arose during doctoral research c.2003, per Biotech Daily) |
Robert Waring | Company Secretary | Since 9 July 2015 | 50+ years in finance/corporate roles; 30+ years as ASX company secretary; 20+ years as ASX director; Company Secretary of Aeris Environmental (ASX: AEI); Director of Oakhill Hamilton Pty Ltd | BEc, CA, FCIS, FFin, FAICD |
Board of Directors
| Name | Role | Appointed | Experience | Education | Other listed boards (3 yrs) |
|---|---|---|---|---|---|
Dr Ronald Shnier | Non-Executive Chairman | 2 Sep 2015 | Radiologist; fellowships at Royal Prince Alfred Hospital (neuroradiology 1989) and UCLA (musculoskeletal 1991); founded one of Australia's first private MRI practices (1991); General Manager then National Director of Mayne's Diagnostic Imaging from 2007; formerly Chief Medical Officer and executive director of I-MED Radiology Network, now non-executive director; NED of Lumitron Technologies | Medical degree and radiology fellowships (degree details not publicly disclosed) | — |
Maurie Stang | Non-Executive Deputy Chairman; co-founder | 12 Dec 2005 | 40+ years building healthcare/biotech companies; Executive Chairman of Lumitron Technologies (unlisted) since 2016; Director of Regional Healthcare Group and Regional Corporate Services; former Chairman of Nanosonics (ASX: NAN) 2007–2022 | — | Aeris Environmental (ASX: AEI) Non-Executive Chairman since 24 July 2002; Nanosonics director until 18 Nov 2022 |
Linda Walters | Non-Executive Director | 20 Dec 2024 | 25+ years senior leadership in life sciences/healthcare; senior roles at Regional Health Care Group and Henry Schein; involved with Vectus since inception, developing operational/commercial capabilities | BEc (Hons), MAICD | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Name | Salary/fees (AUD) | Superannuation (AUD) | Shares (AUD) | Options/rights (AUD) | Total FY2026 (AUD) | Total FY2025 (AUD) |
|---|---|---|---|---|---|---|
Ronald Shnier | 58,036 | 6,964 | 0 | 0 | 65,000 | 65,000 |
Maurie Stang | 49,107 | 5,893 | 0 | 0 | 55,000 | 55,000 |
Linda Walters | 40,179 | 4,821 | 0 | 0 | 45,000 | 23,884 |
Tara Speranza (from 7 May 2026) | 24,808 | 2,977 | 39,064 | 0 | 66,849 | 0 |
Susan Pond (to 27 Nov 2024) | 0 | 0 | 0 | 0 | 0 | 18,520 |
Total KMP | 172,129 | 20,655 | 39,064 | 0 | 231,849 | 162,404 |
Major Shareholders
| Holder | Shares | % of issued capital | Date / source |
|---|---|---|---|
Kefford Holdings Pty Ltd (Kefford family, Melbourne) | 7,122,623 | 11.58 | Substantial holder notice, 27 May 2026 |
Maurie Stang (direct 2,601,952 + indirect 2,574,500) | 5,176,452 | c.8.3 (of c.62.0m) | Director interest notice, 2 Sep 2026 |
Regal Funds Management Pty Ltd & associates | 4,009,280 | 6.52 | Substantial holder notice, 27 May 2026 (reduced from 8.43%) |
Spinite Pty Ltd | — | c.6.5 | Biotech Daily, 31 Jul 2026 |
JB Toro | — | c.6.5 | Biotech Daily, 31 Jul 2026 |
Ajjika Technology Pty Ltd (associated with the late Dr Duggan) | 3,200,000 | c.5.2 | Top-20 (Sep 2025); Biotech Daily |
Bernard Stang | 2,764,500 | c.4.3–5.2 | Top-20 (Sep 2025); Biotech Daily |
J P Morgan Nominees Australia | 2,705,329 | 5.07 (Sep 2025) | FY2025 AR top 20 |
Energy Trading Systems Pty Ltd (The MPF A/C) | 2,562,500 | 4.80 (Sep 2025) | FY2025 AR top 20 |
Towns Corporation Pty Ltd (PAE Family A/C) | 1,984,976 | 3.72 (Sep 2025) | FY2025 AR top 20 |
“—” = not publicly disclosed.
Competitive Landscape
Key Competitors
| Competitor | Segment / indication | Key asset(s) | Stage | Relative positioning vs Vectus |
|---|---|---|---|---|
Boehringer Ingelheim (private) | IPF / PPF | Ofev (nintedanib); Jascayd (nerandomilast, oral PDE4B inhibitor, FDA-approved 7 Oct 2025 — first new IPF approval in over a decade) | Marketed | Category leader; Jascayd slows FVC decline (–106 mL at 18 mg vs –170 mL placebo at 52 weeks) but does not claim reversal |
Roche / Genentech | IPF | Esbriet (pirfenidone) | Marketed (generic erosion) | Incumbent; GI side effects create room for better-tolerated agents |
Bristol Myers Squibb | IPF / PPF | Admilparant (LPA1 antagonist) | Late-stage (industry commentary cites potential for large deals on success) | Well-funded novel mechanism |
United Therapeutics | IPF (add-on) | Tyvaso (inhaled treprostinil) | Seeking label expansion (analyst projections cite 2026) | Inhaled complement to oral antifibrotics |
PureTech Health | IPF | Deupirfenidone (LYT-100) | Phase 3 planned (H1 2026, per industry report) | Improved-tolerability pirfenidone |
Vicore Pharma | IPF | C21 (buloxibutid) | Clinical | Small-cap peer; novel AT2 mechanism |
Avalyn Pharma | IPF | Inhaled pirfenidone/nintedanib | Clinical | Delivery-innovation competitor |
Pliant Therapeutics | IPF | Bexotegrast (αvβ6/αvβ1 integrin) | Discontinued after BEACON-IPF safety issues (2025) | Illustrates high late-stage failure risk |
Mediar Therapeutics (Eli Lilly partnership) | IPF | First-in-class antifibrotic | Preclinical/early clinical; Lilly paid US$99m upfront with up to US$687m milestones (Jan 2025) | Benchmark for early-stage IPF deal values |
XORTX Therapeutics | Kidney disease, gout | XRx-026, XRx-008, VB4-P5 | Clinical | Partner and investee rather than competitor; market cap c.US$3.1m (Oct 2026) |
Dimerix (ASX: DMX) | Kidney (FSGS) | DMX-200 | Phase 3 | ASX fibrosis/kidney peer that progressed via orphan route |
AdAlta (ASX: 1AD) | Formerly IPF | i-body program | Exited IPF for cancer cell therapies | Vectus "assumes the ASX IPF mantle" per Biotech Daily |
Peer Comparison FY2026
| Metric | Vectus (FY2026) | XORTX (latest) | Boehringer Ingelheim |
|---|---|---|---|
Revenue | A$2.77m (A$0.22m ex-XORTX gain) | — | — |
Revenue growth | 478.7% (non-recurring) | — | — |
Net margin | 56.3% (non-cash gain) | Negative (EPS TTM US$-2.58, Yahoo) | — |
R&D intensity | 6.3% of reported income; c.80% of underlying income | — | — |
Market capitalisation | c.A$6.8m (Oct 2026) | c.US$3.1m (Oct 2026) | Private |
Clinical stage of lead asset | Phase I complete; pre-IND | Late-stage (gout) | Marketed |
Recent Developments
Upcoming scheduled items: September 2026 quarterly Appendix 4C (due by 31 Oct 2026); AGM 28 Oct 2026; FDA written pre-IND responses by mid-November 2026.



